Astellas Pays $300m+ For iota In ‘Pharma-Plus’ Push
Sees Magic In ‘Neural Dust’ Implant Tech
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.